semaglutide approved by fda The a pill version of the GLP-1 receptor agonist (Wegovy), making it the first oral GLP-1 agent indicated for weight loss, Novo Nordisk announced on Monday. The once-daily 25 The FDA has approved the

To view or add a comment, sign in Eli Lilly and Company Reports Additional Positive Phase 3 Results for Retatrutide Across Multiple Obesity-Related Conditions On June 6, Eli Lilly and Company announced additional positive pivotal Phase 3 results for its investigational GLP-1/GIP/GCG triple receptor agonist, #Retatrutide

It highlights how GH supports deep sleep, cellular repair, and circadian rhythm stability

The results are not directly comparable because the peptides are not equivalent products

Two other groups received HF diet for 12 months accompanied by NAC for 12 months (HFD + NAC(112)) or 6 months (HFD + NAC(16))